SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
STRO

Sutro Biopharma, Inc. (NASDAQ:STRO)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$8.60-$0.12 (-1.38%)
 
Market cap
$143M
Insider Score
Health Score
Analyst consensus
Listed since
Sep 27, 2018
Market Cap$142.77M-1.7%
Revenue (ttm)$45.11M-57.3%
Net Income-$155.27M+28.4%
EPS-$12.62+51.5%
Shares Out16.60M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume275,896
Open$8.80
Previous Close$8.72
Day's Range$8.46 - $8.99
52-Week Range$7.15 - $43.85
Beta1.55
AnalystsBuy
Price Target$51.33(+496.86%)
Earnings DateMar 22, 2027

About STRO

Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.

Address
111 Oyster Point Boulevard, South San Francisco, CA, 94080, US
Market Cap
143 million
Employees
129
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$89.60K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
1 Buy0 Hold0 SellAvg target $51.33 (+496.9%)

1 firm rating STRO in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Weak
From STRO’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
-1.38%
5 Days
-9.85%
1 Month
-16.42%
6 Months
-66.37%
1 Year
-1.71%

$STRO stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in STRO holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by STRO's directors and management

Net Shares Purchased by Insiders−200k−100k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

STRO Estimated quarterly lobbying spending

Source: U.S. Senate LDA

STRO Revenue by Segment

$18.18MTotal
Collaboration and License Agreements and Supply Agreements$9.10M50.06%
Astellas License and Collaboration Agreement$9.05M49.82%
Vaxcyte Agreements$23.00K0.13%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New STRO patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to STRO from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in STRO

VTIVanguard Morningstar Total Stock Market ETF$3.40M
IWMiShares Russell 2000 ETF$3.32M
FESMFidelity Enhanced Small Cap ETF$1.46M
VXFVanguard Extended Market ETF$1.45M
VFMOVanguard U.S. Momentum Factor ETF$1.32M
IWNiShares Russell 2000 Value ETF$997.36K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from STRO’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
No data yet
—
Analyst Ratings
62% of score
99
News & Sentiment
38% of score
35

News check: Analyst slashed price target 58% while maintaining Outperform rating; company reported Q3 results with mixed implications amid biotech sector volatility.

Recent Insider Activity

Buys
5
Sells
0
Buy Value
$89.60K
Distinct Buyers
5

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

VFLQVanguard U.S. Liquidity Factor ETF0.54%
QQQSInvesco NASDAQ Future Gen 200 ETF0.29%
PQSGPGIM ETF Trust - PGIM QMA Strategic Alpha Small-Cap Growth ETF0.18%
TMEDT. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF0.12%
OMFSInvesco Russell 2000 Dynamic Multifactor ETF0.11%
VFMOVanguard U.S. Momentum Factor ETF0.07%
FSEGFidelity Enhanced Small Cap Growth ETF0.04%
FSEVFidelity Enhanced Small Cap Value ETF0.03%
BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF0.03%
FESMFidelity Enhanced Small Cap ETF0.02%
VHTVanguard Health Care ETF0.00%

Weight is the stock’s share of each fund’s holdings.